首页> 美国卫生研究院文献>Neuro-Oncology >ET-01IL-13 CONJUGATED QUANTUM DOTS FOR THE IDENTIFICATION AND CHARACTERIZATION OF GLIOMA STEM CELLS SOLUBLE RECEPTORS AND EXOSOMES RELEASED BY GBM TUMORS
【2h】

ET-01IL-13 CONJUGATED QUANTUM DOTS FOR THE IDENTIFICATION AND CHARACTERIZATION OF GLIOMA STEM CELLS SOLUBLE RECEPTORS AND EXOSOMES RELEASED BY GBM TUMORS

机译:ET-01IL-13共轭量子点用于GBM肿瘤释放的胶质瘤干细胞可溶性受体和外显子的鉴定和表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glioblastoma Multiforme is an aggressive brain tumor combining high infiltrative properties with a heterogenous nature making it challenging to identify and remove them by surgery and increasing their resistance to other conventional therapies. GBM tumors are known to express the IL-13Rα2 receptors which we have used to target nanoliposomes for enhancing theranostic efficacy. In our present investigation we utilized interleukin-13 ( IL-13) conjugated quantum dots (IL-13QD) to selectively bind the glioma stem cells in culture and the soluble receptor in a medium and the exosomes released in a biological fluid. The binding phenomenon was characterized by various techniques like atomic force microscopy, dynamic light scattering method, electron microscopy and fluorescent microscopy. Investigation was also performed to determine the release of soluble IL-13Rα2 receptor and IL-13Rα2 expressing exosomes from the glioma stem cells in the culture media and in the cerebrospinal fluid. After confirming the presence of soluble receptor by immunoblots and ELISA and exosomes by electron microscopy and dynamic light scattering method, in vitro studies were performed with the IL-13QD in a media containing the exosomes and soluble receptors to investigate the binding and aggregation properties of the IL-13QD. Our investigation revealed the aggregation properties of the IL-13QD in the presence of soluble receptor and exosomes indicating a correlation between the receptor expression and aggregation and dissociation of quantum dots. Further studies are in progress with patient samples that would lead to a development of a biomarker and a therapeutic agent for the highly malignant brain tumors.
机译:胶质母细胞瘤是一种侵袭性脑肿瘤,具有高浸润性和异质性,使其难以通过手术鉴定和清除,并增加了其对其他常规疗法的抵抗力。已知GBM肿瘤表达IL-13Rα2受体,我们已将其用于靶向纳米脂质体以增强治疗功效。在我们目前的研究中,我们利用白介素13(IL-13)共轭量子点(IL-13QD)选择性结合培养中的神经胶质瘤干细胞和培养基中的可溶性受体以及生物液中释放的外泌体。结合现象用原子力显微镜,动态光散射法,电子显微镜和荧光显微镜等各种技术表征。还进行了研究以确定在培养基和脑脊髓液中神经胶质瘤干细胞中可溶性IL-13Rα2受体和IL-13Rα2表达外泌体的释放。通过免疫印迹和ELISA确认可溶性受体的存在以及通过电子显微镜和动态光散射法确认外泌体的存在后,在含有外泌体和可溶性受体的培养基中对IL-13QD进行了体外研究,以研究其结合和聚集特性。 IL-13QD。我们的研究揭示了在可溶性受体和外泌体存在下IL-13QD的聚集特性,表明受体表达与量子点聚集和解离之间存在相关性。对患者样品的进一步研究正在进行中,这将导致针对高度恶性脑肿瘤的生物标志物和治疗剂的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号